Health care–associated pneumonia in the intensive care unit: Guideline-concordant antibiotics and outcomes

Journal of Critical Care

Volumn 36, Issue , 2016, Pages 265-271

  Attridge, Russell T ^a,b   Frei, Christopher R ^c,d   Pugh, Mary Jo V ^b,d   Lawson, Kenneth A ^c   Ryan, Laurajo ^c,d   Anzueto, Antonio ^b,d   Metersky, Mark L ^e   Restrepo, Marcos I ^b,d   Mortensen, Eric M ^f,g  

^a UNIVERSITY OF THE INCARNATE WORD   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^f VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Antibiotic therapy; Critical care; Guideline concordant therapy; Health outcomes; Pneumonia

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; AZITHROMYCIN; AZTREONAM; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; GATIFLOXACIN; GENTAMICIN; HYPERTENSIVE AGENT; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TIMENTIN; TOBRAMYCIN; VANCOMYCIN; ANTIINFECTIVE AGENT; VASOCONSTRICTOR AGENT;

AGED; ARTICLE; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; FEMALE; GUIDELINE CONCORDANT; HEALTH CARE ASSOCIATED PNEUMONIA; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PROGNOSIS; RISK FACTOR; VERY ELDERLY; CASE CONTROL STUDY; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; GOVERNMENT; HOSPITALIZATION; INTENSIVE CARE; MULTIVARIATE ANALYSIS; ODDS RATIO; PNEUMONIA, BACTERIAL; PROTOCOL COMPLIANCE; PUBLIC HOSPITAL; RETROSPECTIVE STUDY; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; COMMUNITY-ACQUIRED INFECTIONS; CRITICAL CARE; CROSS INFECTION; FEMALE; GUIDELINE ADHERENCE; HOSPITALIZATION; HOSPITALS, VETERANS; HUMANS; INTENSIVE CARE UNITS; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; ODDS RATIO; PNEUMONIA, BACTERIAL; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS; VASOCONSTRICTOR AGENTS;

EID: 84994323503     PISSN: 08839441     EISSN: 15578615     Source Type: Journal    
DOI: 10.1016/j.jcrc.2016.08.004     Document Type: Article

References (40)

1. [1] American Thoracic Society, Infectious Diseases Society of America: guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171 (2005), 388–416.
2. [2] Kollef, MH, Shorr, A, Tabak, YP, Gupta, V, Liu, LZ, Johannes, RS, Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 128 (2005), 3854–3862.
3. [3] Micek, ST, Kollef, KE, Reichley, RM, Roubinian, N, Kollef, MH, Health care–associated pneumonia and community-acquired pneumonia: a single-center experience. Antimicrob Agents Chemother 51 (2007), 3568–3573.
4. [4] Carratala, J, Mykietiuk, A, Fernandez-Sabe, N, Suarez, C, Dorca, J, Verdaguer, R, et al. Health care–associated pneumonia requiring hospital admission: epidemiology, antibiotic therapy, and clinical outcomes. Arch Intern Med 167 (2007), 1393–1399.
5. [5] Grenier, C, Pepin, J, Nault, V, Howson, J, Fournier, X, Poirier, M, et al. Impact of guideline-consistent therapy on outcome of patients with healthcare-associated and community-acquired pneumonia. J Antimicrob Chemother 66 (2011), 1617–1624.
6. [6] Garcia-Vidal, C, Viasus, D, Roset, A, Adamuz, J, Verdaguer, R, Dorca, J, et al. Low incidence of multidrug-resistant organisms in patients with healthcare-associated pneumonia requiring hospitalization. Clin Microbiol Infect 17 (2011), 1659–1665.
7. [7] Chalmers, JD, Taylor, JK, Singanayagam, A, Fleming, GB, Akram, AR, Mandal, P, et al. Epidemiology, antibiotic therapy, and clinical outcomes in health care–associated pneumonia: a UK cohort study. Clin Infect Dis 53 (2011), 107–113.
8. [8] Maruyama, T, Fujisawa, T, Okuno, M, Toyoshima, H, Tsutsui, K, Maeda, H, et al. A new strategy for healthcare-associated pneumonia: a 2-year prospective multicenter cohort study using risk factors for multidrug-resistant pathogens to select initial empiric therapy. Clin Infect Dis 57 (2013), 1373–1383.
9. [9] Polverino, E, Torres, A, Menendez, R, Cilloniz, C, Valles, JM, Capelastegui, A, et al. Microbial aetiology of healthcare associated pneumonia in Spain: a prospective, multicentre, case-control study. Thorax 68 (2013), 1007–1014.
10. [10] Shindo, Y, Ito, R, Kobayashi, D, Ando, M, Ichikawa, M, Shiraki, A, et al. Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia. Am J Respir Crit Care Med 188 (2013), 985–995.
11. [11] Valles, J, Martin-Loeches, I, Torres, A, Diaz, E, Seijas, I, Lopez, MJ, et al. Epidemiology, antibiotic therapy and clinical outcomes of healthcare-associated pneumonia in critically ill patients: a Spanish cohort study. Intensive Care Med 40 (2014), 572–581.
12. [12] Mandell, LA, Wunderink, RG, Anzueto, A, Bartlett, JG, Campbell, GD, Dean, NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44:Suppl. 2 (2007), S27–S72.
13. [13] Attridge, RT, Frei, CR, Restrepo, MI, Lawson, KA, Ryan, L, Pugh, MJV, et al. Guideline-concordant therapy and outcomes in healthcare-associated pneumonia. Eur Respir J 38 (2011), 878–887.
14. [14] Webb, BJ, Dangerfield, BS, Pasha, JS, Agrwal, N, Vikram, HR, Guideline-concordant antibiotic therapy and clinical outcomes in healthcare-associated pneumonia. Respir Med 106 (2012), 1606–1612.
15. [15] Madaras-Kelly, KJ, Remington, RE, Sloan, KL, Fan, VS, Guideline-based antibiotics and mortality in healthcare-associated pneumonia. J Gen Intern Med 27 (2012), 845–852.
16. [16] Rothberg, MB, Zilberberg, MD, Pekow, PS, Priya, A, Haessler, S, Belforti, R, et al. Association of guideline-based antimicrobial therapy and outcomes in healthcare-associated pneumonia. J Antimicrob Chemother, 2015, 701573–701579.
17. [17] Falcone, M, Corrao, S, Licata, G, Serra, P, Venditti, M, Clinical impact of broad-spectrum empirical antibiotic therapy in patients with healthcare-associated pneumonia: a multicenter interventional study. Intern Emerg Med 7 (2012), 523–531.
18. [18] Kett, DH, Cano, E, Quartin, AA, Mangino, JE, Zervos, MJ, Peyrani, P, et al. Implementation of guidelines for management of possible multidrug-resistant pneumonia in intensive care: an observational, multicentre cohort study. Lancet Infect Dis 11 (2011), 181–189.
19. [19] Deyo, RA, Cherkin, DC, Ciol, MA, Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45 (1992), 613–619.
20. [20] Troitino, AX, Porhomayon, J, El-Solh, AA, Guideline-concordant antimicrobial therapy for healthcare-associated pneumonia: a systematic review and meta-analysis. Lung 191 (2013), 229–237.
21. [21] Laing, R, Coles, C, Chambers, S, Frampton, C, Jennings, L, Karalus, N, et al. Community-acquired pneumonia: influence of management practices on length of hospital stay. Intern Med J 34 (2004), 91–97.
22. [22] Chalmers, JD, Al-Khairalla, M, Short, PM, Fardon, TC, Winter, JH, Proposed changes to management of lower respiratory tract infections in response to the Clostridium difficile epidemic. J Antimicrob Chemother 65 (2010), 608–618.
23. [23] Ray, WA, Murray, KT, Hall, K, Arbogast, PG, Stein, CM, Azithromycin and the risk of cardiovascular death. N Engl J Med 366 (2012), 1881–1890.
24. [24] Asadi, L, Sligl, WI, Eurich, DT, Colmers, IN, Tjosvold, L, Marrie, TJ, et al. Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis. Clin Infect Dis 55 (2012), 371–380.
25. [25] Mortensen, EM, Halm, EA, Pugh, MJ, Copeland, LA, Metersky, M, Fine, MJ, et al. Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia. JAMA 311 (2014), 2199–2208.
26. [26] Attridge, RT, Frei, CR, Health care-associated pneumonia: an evidence-based review. Am J Med 124 (2011), 689–697.
27. [27] Depuydt, P, Putman, B, Benoit, D, Buylaert, W, De Paepe, P, Nursing home residence is the main risk factor for increased mortality in healthcare-associated pneumonia. J Hosp Infect 77 (2011), 138–142.
28. [28] Ding, YY, Abisheganaden, J, Chong, WF, Heng, BH, Lim, TK, Short-term mortality among older persons hospitalized for pneumonia: influence of baseline patient characteristics beyond severity of illness. J Hosp Med 7 (2012), 211–217.
29. [29] Shorr, AF, Zilberberg, MD, Micek, ST, Kollef, MH, Prediction of infection due to antibiotic-resistant bacteria by select risk factors for health care–associated pneumonia. Arch Intern Med 168 (2008), 2205–2210.
30. [30] Shorr, AF, Myers, DE, Huang, DB, Nathanson, BH, Emons, MF, Kollef, MH, A risk score for identifying methicillin-resistant Staphylococcus aureus in patients presenting to the hospital with pneumonia. BMC Infect Dis, 13, 2013, 268.
31. [31] Schreiber, MP, Chan, CM, Shorr, AF, Resistant pathogens in nonnosocomial pneumonia and respiratory failure: is it time to refine the definition of health-care-associated pneumonia?. Chest 137 (2010), 1283–1288.
32. [32] Madaras-Kelly, KJ, Remington, RE, Fan, VS, et al. Predicting antibiotic resistance to community-acquired pneumonia antibiotics in culture-positive patients with healthcare-associated pneumonia. J Hosp Med 7 (2012), 195–202.
33. [33] Giannella, M, Pinilla, B, Capdevila, JA, Martinez Alarcon, J, Munoz, P, Lopez, AJ, Pneumonia treated in the internal medicine department: focus on healthcare-associated pneumonia. Clin Microbiol Infect 18 (2012), 786–794.
34. [34] Chalmers, JD, Rother, C, Salih, W, Ewig, S, Healthcare-associated pneumonia does not accurately identify potentially resistant pathogens: a systematic review and meta-analysis. Clin Infect Dis 58 (2014), 330–339.
35. [35] Aliberti, S, Cilloniz, C, Chalmers, JD, Zanaboni, AM, Cosentini, R, Tarsia, T, et al. Multidrug-resistant pathogens in hospitalised patients coming from the community with pneumonia: a European perspective. Thorax 68 (2013), 997–999.
36. [36] Webb, BJ, Dascomb, K, Stenehjem, E, Vikram, HR, Agrwal, N, Sakata, K, et al. Derivation and multicenter validation of the drug resistance in pneumonia clinical prediction score. Antimicrob Agents Chemother 60 (2016), 2652–2663.
37. [37] Schlueter, M, James, C, Dominguez, A, Tsu, L, Seymann, G, Practice patterns for antibiotic de-escalation in culture-negative healthcare-associated pneumonia. Infection 8 (2010), 357–362.
38. [38] Ewig, S, Welte, T, Chastre, J, Torres, A, Rethinking the concepts of community-acquired and health-care-associated pneumonia. Lancet Infect Dis 10 (2010), 279–287.
39. [39] Fine, MJ, Auble, TE, Yealy, DM, Hanusa, BH, Weissfeld, LA, Singer, DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 336 (1997), 243–250.
40. [40] Lim, WS, van der Eerden, MM, Laing, R, Boersma, WG, Karalus, N, Town, GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 58 (2003), 377–382.